TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04934995

Intervention type: OTHER
Intervention: Blood Pressure Cuff
Description: After obtaining consent and confirming eligibility, Blood Pressure cuffs will be used as specified below:~Cuff size: large BP cuffs will be the default size for both arm and ankle measurements, but can be changed as clinically indicated based on circumferences of limbs Cuff location: BP cuffs will be placed on the contralateral arm to the main peripheral IV following standard procedures. Left ankle cuff will be placed underneath intermittent pneumatic compression cuffs Ankle blood pressure monitor screen will be covered. Thus, anesthesia providers will not be able to make any clinical decisions based on ankle blood pressures but arm blood pressure (standard) instead.
Study: NCT06461195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring of patients
Description: Data from a spirometer and a stethoscope are captured to develop algorithms to detect and classify respiration sounds to support therapists and patients in future therapy.
Study: NCT06154759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watson Human Caring Model-based psychoeducation
Description: It is a psychoeducation program based on the Watson human care model, one of the theories of the nursing profession, that includes healing processes, and consists of sessions that address the hopelessness, death anxiety and care burden of individuals.
Study: NCT06699680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX019
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX019
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06698549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558
Description: Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558
Description: Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558
Description: Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558
Description: Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)
Study: NCT06698874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ds-MCE and EGD examinations
Description: Sequentially performing ds-MCE and EGD examinations on enrolled participants.
Study: NCT06699654

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: A gel without active Spirulina components applied as a control intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spirulina Gel
Description: A conventional Spirulina gel formulation applied as a periodontal therapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina Nanoparticles Gel
Description: A novel Spirulina nanoparticles gel formulation applied as a periodontal therapy.
Study: NCT06700317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HSS1
Description: Surgery performed using HSS1
Study: NCT06698588

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 Fish Oil supplements
Description: Wileys Easy Swallow Mini Softgel capsules, dose 3 caps/day, providing 945mg/day long-chain omega-3 (540mg EPA, 405mg DHA).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: high-oleic sunflower oil (which broadly matches the overall fatty acid composition of typical UK diet), matched with active treatment for appearance and taste.
Study: NCT05940298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous injection of [99mTc]Tc-DB8
Description: One single intravenous injection of \[99mTc\]Tc-DB8, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
Study: NCT05270265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pvs25-IMX313/Matrix-M1
Description: Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pvs25-IMX313/Matrix-M1
Description: Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
Study: NCT06415591

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous electrical nerve field stimulation
Description: FDA-approved acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous electrical nerve field stimulation
Description: FDA-approved acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal.
Study: NCT05996627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Given PO
Study: NCT06125236

Intervention type: OTHER
Intervention: Visit at D90
Description: Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
Study: NCT05142917

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand motor task
Description: Various type of hand motor tasks are applied to stroke patients.
Study: NCT05832398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX , FOLFIRI or FOLFOXIRI regimens
Description: FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFIRI (irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFOXIRI (irinotecan 150mg/m2, and folinic acid 400mg/m2, oxaliplatin 85 mg/m2, 5-fluorouracil 3200 mg/m2 48-h continuous infusion) for 6 cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX or CapeOX regimens
Description: FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle CaoeOX (Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)
Study: NCT05485376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary Artery Catheter
Description: The pulmonary artery catheter (PAC) is a diagnostic instrument that enables continuous hemodynamic monitoring of cardiac filling pressures, cardiac output, and pulmonary pressures.
Study: NCT05996627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT06532097

Intervention type: BEHAVIORAL
Intervention: Physical and behavioral smartwatch-based activation
Description: We used smartwatches to provide an interactive tool for delivering a mixed intervention of physical and behavioral activation, with the former addressing physical activity level and the latter pleasant activities including and beyond physical activity (e.g., social, relaxing activities). Moreover, given the relationship with physical activity level, we additionally incorporated digital insomnia exercises that have also shown large effects in the amelioration of depression.
Study: NCT06451952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual darkness
Description: Chronotheraphy
Study: NCT05878288

Intervention type: DRUG
Group type: OTHER
Intervention: Cemiplimab
Description: Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
Study: NCT05721105

Intervention type: OTHER
Intervention: Quality of life assessment using questionnaires
Description: Several quality of life questionnaires will be submitted to the patients and their parents. The questionnaires will be adapted to the age of the patients.

Intervention type: OTHER
Intervention: Quality of life assessment using questionnaires
Description: Several quality of life questionnaires will be submitted to the patients and their parents. The questionnaires will be adapted to the age of the patients.
Study: NCT06497010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: PD-1
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: InnoPCV
Description: Intramuscular (IM) injection
Study: NCT04637763

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CB-010
Description: CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CB-010
Description: CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion
Study: NCT05270265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pvs25-IMX313/Matrix-M1
Description: Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
Study: NCT05192044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast track Care pancreatico-duodenectomy.
Description: Enhanced recovery after pancreatico-duodenectomy, with early oral intake, mobilization \& discharge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Conventional Care
Study: NCT06135506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: free-hand ridge splitting
Description: Midcrestal incision will be followed by reflection of full thickness flap. Midcrestal cut without vertical osteotomy will be done using piezosurgery unit, and then the cut will be extended deep to the implant length. The ridge will be expanded progressively using bone wedges. Dental implant fixtures will be placed stably with 1 mm minimal thickness of buccal bone plate. Surgical site will be completely closed, and wound edges will be sutured in a tension-free way.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI/guided ridge splitting
Description: The patient specific guides will be placed and fixed by monocortical osteosynthesis screws at the pre-planned positions at the labial buccal mucosa.~A midcrestal cut will be performed on the crest of alveolar ridge guided by the guide slits. The cuts will be expanded progressively using bone wedges through the guide slits gradually lateralize and expand the labial alveolar plate of bone, so the labial cortex will move through the intentionally created micro gap till it touches the fitting aspect of the patient specific guide. Implant drills will be inserted through the guiding holes in the surgical guide and the implant osteotomy sites will be prepared. Finally, implants will be inserted in the osteotomy sites using torque-wrench in a self-tapping fashion engaging palatal and basal bone for primary stability.
Study: NCT03643198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANTIBIOTIC (METRONIDAZOLE AND CIPROFLOXACIN)
Description: The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CONTROL
Description: NO treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: NO treatment
Study: NCT04691531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The use of classical Gauge 22 needle
Description: After induction of general anesthesia, patients will undergo caudal block by using classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The use of classical Gauge 27 needle
Description: After induction of general anesthesia, patients will undergo caudal block by using Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
Study: NCT05028478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN202
Description: Participants will receive CN202 by IV infusion on Day 1 of each cycle (once every 2 weeks). The 4 planned dose levels are 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg
Study: NCT06275464

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BT-600
Description: NaviCap device containing liquid formulation of Tofacitinib

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BT-600
Description: NaviCap device containing liquid formulation of Tofacitinib
Study: NCT05142917

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Hand motor task
Description: Various type of hand motor tasks are applied to stroke patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand motor task
Description: Various type of hand motor tasks are applied to stroke patients.
Study: NCT04452305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting
Description: Spermatogonial stem cell transplant and testicular tissue grafting is performed to produce sperm.
Study: NCT06275464

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BT-600
Description: NaviCap device containing liquid formulation of Tofacitinib

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BT-600
Description: NaviCap device containing liquid formulation of Tofacitinib

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: BT-600 Placebo
Description: NaviCap device containing placebo formulation

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: BT-600 Placebo
Description: NaviCap device containing placebo formulation

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: BT-600 Placebo
Description: NaviCap device containing placebo formulation

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: BT-600 Placebo
Description: NaviCap device containing placebo formulation
Study: NCT06091449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fidelity simulation
Description: Within the scope of high reality simulation application; The ideal number of students to take part in each simulation was determined to be 10. On the simulation day, the researchers responsible for the simulation application will introduce the environment and the tools and equipment they will use in the simulation application, so that they can make preliminary preparations for the students. It will last 60 minutes in total, including preliminary information (10 minutes), simulation time (15 minutes) and evaluation/analysis session (35 minutes).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fidelity simulation
Description: Within the scope of high reality simulation application; The ideal number of students to take part in each simulation was determined to be 10. On the simulation day, the researchers responsible for the simulation application will introduce the environment and the tools and equipment they will use in the simulation application, so that they can make preliminary preparations for the students. It will last 60 minutes in total, including preliminary information (10 minutes), simulation time (15 minutes) and evaluation/analysis session (35 minutes).
Study: NCT06357429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Cold application was applied to the LI4 acupressure point on the patients' hands using an ice battery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Cold application was applied to the LI4 acupressure point on the patients' hands using an ice battery.
Study: NCT04882124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.
Study: NCT06091449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: For the virtual reality-based simulation application, students can log in to the virtual reality-based simulation program prepared in line with the Diabetes Mellitus scenario using their username and password; They will receive modular training integrated into the simulation. The expected time for students to complete the modular training is 30 minutes. Students who complete the module will be asked to take a 10-minute break and then participate in a virtual reality-based simulation application.The application of high-fidelity simulation is the same in both groups.
Study: NCT04882124

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device
Study: NCT04904640

Intervention type: DEVICE
Intervention: Hip stem
Description: In every hip (with appropriate CT scan), 3 different stem designs will be positioned using a 3D Ct based software for surgical pre-operative planning.

Intervention type: DEVICE
Intervention: Hip stem
Description: In every hip (with appropriate CT scan), 3 different stem designs will be positioned using a 3D Ct based software for surgical pre-operative planning.

Intervention type: DEVICE
Intervention: Hip stem
Description: In every hip (with appropriate CT scan), 3 different stem designs will be positioned using a 3D Ct based software for surgical pre-operative planning.
Study: NCT03659708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lyon-VTE score
Description: follow-up at 3 months, 5 months, 7 months during pregnancy and 3 months and 12 months after delivery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recommendations currently available
Description: follow-up at 7 months during pregnancy and 3 months and 12 months after delivery.
Study: NCT04886505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolytic eCLIPs Bifurcation System
Description: The electrolytic eCLIPs bifurcation system will be implanted into patients with bifurcated saccular intra-cranial aneurysms.
Study: NCT06006143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will receive a prescription for varenicline and will meet with a clinical pharmacist and addiction psychiatrist for further support
Study: NCT05689671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg i.v. q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 100 mg/m² i.v. qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5-6 i.v. q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg i.v. q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m² i.v. q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5-6 i.v. q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m² i.v. q3w
Study: NCT06269185

Intervention type: DRUG
Intervention: Infliximab
Description: Infliximab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis

Intervention type: DRUG
Intervention: Adalimumab
Description: Adalimumab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
Study: NCT06186895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
Study: NCT05000866

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication skills training video
Description: The communication skills training video component is designed to be self-delivered. Four couples are depicted in separate scenes discussing HIV testing, drug use, sexual agreements, and drug use during sex. Each scene is viewed twice. In the initial viewing, the couple in the video makes one or more communication errors. The scene is subsequently viewed a second time and the couple utilizes more effective communication skills, resulting in a more adaptive resolution. Each scene is introduced by a narrator who points out communication errors and orients viewers to skills utilized in adaptive versions of each scene.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication skills training video
Description: The communication skills training video component is designed to be self-delivered. Four couples are depicted in separate scenes discussing HIV testing, drug use, sexual agreements, and drug use during sex. Each scene is viewed twice. In the initial viewing, the couple in the video makes one or more communication errors. The scene is subsequently viewed a second time and the couple utilizes more effective communication skills, resulting in a more adaptive resolution. Each scene is introduced by a narrator who points out communication errors and orients viewers to skills utilized in adaptive versions of each scene.